Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most medication-use dosing/timing/with-food statements are supported by the provided label excerpts, but multiple exercise/swimming-related claims and quantitative statements (e.g., effects last 24 hours, swimming safety/encouragement, specific risk percentages, and “no interaction issues”) are not supported by the provided prescribing information and cannot be verified from the excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is typically taken once daily.
Section 2.1: “The recommended starting dose of LIPITOR is 10 or 20 mg once daily… The dosage range… is 10 to 80 mg once daily.”
Lipitor can be taken at any time of day but ideally at the same time each day.
Section 2.1: “LIPITOR can be administered as a single dose at any time of the day…” (label does not explicitly state “ideally at the same time each day,” but “any time of day” is supported).
Lipitor can be taken with or without food.
Section 2.1: “with or without food”.
The usual adult starting dose of Lipitor for cholesterol management is 10–20 mg.
Section 2.1: “The recommended starting dose of LIPITOR is 10 or 20 mg once daily…”
A doctor may adjust the Lipitor dose up to 80 mg based on response and blood tests.
Section 2.1: “dosage range… is 10 to 80 mg once daily.” (label excerpts provided do not explicitly mention “based on response and blood tests,” though dose range supports dose adjustment).
Lipitor should not be taken more than once per day unless directed by a physician.
Section 2.1: “once daily” single dose at any time of day (supports once-daily regimen; label excerpt does not address “unless directed,” so this is inferred from dosing frequency).
Taking Lipitor more than once per day increases risks like muscle damage without added benefit.
Not directly supported by the provided excerpts (label warns risk of myopathy/rhabdomyolysis with certain concomitant conditions/drugs, but does not address higher frequency dosing).
Rarely, Lipitor causes muscle pain (myalgia).
Section 6.1: “myalgia (0.7%)” listed among adverse reactions leading to discontinuation (described as “common… led to treatment discontinuation”).
Rarely, Lipitor causes muscle weakness.
Not directly supported as stated in the provided excerpts (label excerpt lists myopathy/rhabdomyolysis but does not provide “muscle weakness” as an adverse reaction term with similar support).
Those over 65 have a higher risk of Lipitor muscle-related adverse effects.
Not supported by the provided excerpts (no geriatric risk statement in supplied sections).
People with kidney issues have a higher risk of Lipitor muscle-related adverse effects.
Not directly supported by the provided excerpts (label excerpt mentions rhabdomyolysis with acute renal failure, but does not state higher risk in kidney disease).
People taking certain other drugs, such as fibrates, have a higher risk of Lipitor muscle-related adverse effects.
Section 7: “The risk of myopathy… is increased with concurrent administration of fibric acid derivatives…” (fibrates are fibric acid derivatives).
Regular bloodwork monitors for Lipitor-related adverse effects.
Section 5.2: “It is recommended that liver function tests be performed prior to and at 12 weeks following both initiation… and any elevation of dose… and periodically…” (label excerpt provided focuses on liver tests; “regular bloodwork” for all adverse effects is broader than excerpt).
Unsupported Statements
Swimming is generally safe for people taking Lipitor.
No swimming/exercise safety information is present in the provided label excerpts.
Swimming is encouraged as aerobic exercise for people on Lipitor.
No exercise recommendations or endorsements are present in the provided label excerpts.
Swimming helps lower cholesterol and supports heart health while on Lipitor.
No statements about swimming improving cholesterol or heart health are present in the provided label excerpts.
There are no specific restrictions on swimming frequency or timing relative to Lipitor dosing.
No swimming frequency/timing guidance or interaction statement with exercise is present in the provided label excerpts.
Lipitor's effects last 24 hours.
The provided label excerpt does not state an effect duration of 24 hours.
Swimming before or after a Lipitor dose has no interaction issues.
No interaction information between exercise timing and atorvastatin dosing is present in the provided label excerpts.
Some people take Lipitor at night to minimize daytime muscle soreness during activities like swimming.
No label statements support taking Lipitor at night to manage exercise-related soreness.
Statins can slightly raise dehydration risk during intense exercise.
No label excerpt addresses dehydration risk during intense exercise.
Muscle pain or weakness could worsen with swimming due to repetitive arm/leg motions.
No label excerpt links exercise mechanics (swimming motions) to worsening muscle adverse effects.
Myalgia or muscle weakness affects about 1–5% of users.
The provided label excerpt gives myalgia leading to discontinuation as 0.7% (and does not provide a 1–5% overall prevalence for muscle pain/weakness).
Stopping Lipitor and contacting a doctor is advised if unexplained soreness, dark urine, or cramps occur after swimming, as these signal potential rhabdomyolysis.
The provided label excerpt does not provide this specific action guidance tied to swimming or symptoms timing; it generally discusses rhabdomyolysis/myopathy and temporarily withholding/discontinuing in certain acute serious conditions, but not the exact symptom list and “after swimming” context.
Those over 65 have a higher risk of Lipitor muscle-related adverse effects.
No age-related risk statement is present in the provided label excerpts.
People with kidney issues have a higher risk of Lipitor muscle-related adverse effects.
No kidney-disease risk statement is present in the provided label excerpts.
A target of 150 minutes of moderate swimming weekly (e.g., 5 sessions of 30 minutes) can amplify Lipitor's cholesterol-lowering effects.
No exercise quantity target or amplification of cholesterol-lowering effect by swimming is present in the provided label excerpts.
Combining exercise with diet is recommended for optimal outcomes with Lipitor, and exercise alone boosts HDL and aids weight control.
No such recommendation or specific exercise/HDL/weight control claims are present in the provided label excerpts.
Contradictions
Low
AI Statement
Taking Lipitor more than once per day increases risks like muscle damage without added benefit.
Label Reference
No contradiction can be confirmed from the provided excerpts; however, the claim is not supported and also not directly contradicted by provided labeling.
Important Omissions
Key contraindications and warnings not addressed by the AI claims, including pregnancy contraindication, nursing contraindication, and active liver disease/hypersensitivity, as well as liver function test recommendations and the specific hemorrhagic stroke risk context associated with higher-dose atorvastatin (80 mg) in patients with recent stroke/TIA (from supplied label excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Medication-use regimen aspects are largely consistent with dosing instructions (once-daily, any time, with/without food). However, multiple unsupported exercise/swimming-related claims and quantitative adverse-effect prevalence/duration/interaction assertions could mislead users about safety and when to seek care; the provided excerpts do not substantiate these exercise-specific points.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous claims about swimming/exercise safety, timing, interaction, and effect duration are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is explicitly supported in the supplied label excerpts (e.g., once-daily dosing range, with/without food, and label-supported risks such as myopathy/rhabdomyolysis and drug-interaction cautions). Remove or rephrase exercise/swimming-specific safety, prevalence, and timing/duration assertions unless they are directly supported by the label text provided.